Published on 28 Mar 2024 on Zacks via Yahoo Finance
Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates
It was a busy week for the biotech sector, with lots of study data readouts and regulatory updates. Among these, Praxis Precision Medicines, Inc. PRAX and Viking Therapeutics, Inc. VKTX gain on study results.
Recap of the Week’s Most Important Stories:
Setback for Regeneron: Regeneron Pharmaceuticals, Inc. REGN suffered a setback as the FDA issued Complete Response Letters (CRLs) for its biologics license application (BLA) for odronextamab. The BLA is seeking the approval of the candidate in relapsed/refractory (R/R) follicular lymphoma (FL) and in R/R diffuse large B-cell lymphoma (DLBCL), each after two or more lines of systemic therapy.